Symbol: SUNPHARMA
Month: 2025-04
Start Price: ₹1698.35
End Price: ₹1832.30
12M Return: 7.89%
6M Return: 7.89%
3M Return: 7.89%
Volatility: 0.329
Sharpe Ratio: 3.391
Max Drawdown: -0.067
Peer Correlation (DRREDDY): 0.7057
Peer Correlation (DIVISLAB): 0.4163
Peer Correlation (HINDUNILVR): -0.0778
Average Peer Correlation: 0.3481

Generate a short summary and suggest whether to BUY, SELL, or HOLD.

--- LLM Output ---
**Summary:**

Sun Pharma (SUNPHARMA) has shown a positive trend in the past 12 months, with a return of 7.89%. The stock's volatility is relatively low at 0.329, and its Sharpe Ratio of 3.391 indicates that the returns are generated with relatively low risk. The maximum drawdown of -0.067 suggests that the stock has been resilient during market downturns. In terms of peer correlation, SUNPHARMA has a high correlation with DRREDDY (0.7057) and a moderate correlation with DIVISLAB (0.4163), but a negative correlation with HINDUNILVR (-0.0778).

**Recommendation:**

Based on the analysis, I would suggest a **BUY** recommendation for SUNPHARMA. The stock's consistent returns, low volatility, and high Sharpe Ratio indicate that it is a relatively stable and attractive investment opportunity. The positive correlation with DRREDDY and moderate correlation with DIVISLAB suggest that SUNPHARMA is well-positioned within its peer group. The negative correlation with HINDUNILVR may be a minor concern, but it does not outweigh the overall positive outlook. Overall, SUNPHARMA appears to be a good investment opportunity for those looking for a relatively stable and growth-oriented stock in the pharmaceutical sector.